Completed NA INTERVENTIONAL 2-arm NCT01436136

Reducing Cardiovascular Disease (CVD) Risk in HIV on Antiretroviral Therapy Over 12 Months (CVD)

Effectiveness of Team Intervention Over 12 Months in Reducing Modifiable CVD Risk Factors on Framingham 10yr Risk Scores Outcomes in HIV-1 Subjects on Antiretroviral Therapy

Sponsor: Holdsworth House Medical Practice

Conditions Cardiovascular Disease HIV-1 Infection

Interventions Control Intervention Group

Updated 5 times since 2017 Last updated: May 10, 2015 Started: Oct 31, 2011 Primary completion: Jun 30, 2014 Completion: Jun 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Cardiovascular Disease and HIV-1 Infection and is currently completed. Holdsworth House Medical Practice leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Holdsworth House Medical Practice

Data source: Holdsworth House Medical Practice

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sydney, Australia